Literature DB >> 31884019

Angiotensin II and aldosterone activate retinal microglia.

Indrajeetsinh Rana1, Varaporn Suphapimol2, Jack R Jerome2, Dean M Talia3, Devy Deliyanti2, Jennifer L Wilkinson-Berka4.   

Abstract

Microglial cells are important contributors to the neuroinflammation and blood vessel damage that occurs in ischemic retinopathies. We hypothesized that key effectors of the renin-angiotensin aldosterone system, angiotensin II (Ang II) and aldosterone, increase the density of microglia in the retina and stimulate their production of reactive oxygen species (ROS) as well as pro-angiogenic and pro-inflammatory factors. Two animal models were studied that featured up-regulation of Ang II or aldosterone and included transgenic Ren-2 rats which overexpress renin and Ang II in tissues including the retina, and Sprague Dawley rats with ischemic retinopathy and infused with aldosterone. Complementary studies were performed in primary cultures of retinal microglia from neonatal Sprague Dawley rats exposed to hypoxia (0.5% O2) and inhibitors of the angiotensin type 1 receptor (valsartan), the mineralocorticoid receptor (spironolactone) or aldosterone synthase (FAD286). In both in vivo models, the density of ionized calcium-binding adaptor protein-1 labelled microglia/macrophages was increased in retina compared to genetic or vehicle controls. In primary cultures of retinal microglia, hypoxia increased ROS (superoxide) levels as well as the expression of the NADPH oxidase (NOX) isoforms, NOX1, NOX2 and NOX4. The elevated levels of ROS as well as NOX2 and NOX4 were reduced by all of the treatments, and valsartan and FAD286 also reduced NOX1 mRNA levels. A protein cytokine array of retinal microglia revealed that valsartan, spironolactone and FAD286 reduced the hypoxia-induced increase in the potent pro-angiogenic and pro-inflammatory agent, vascular endothelial growth factor as well as the inflammatory factors, CCL5 and interferon γ. Valsartan also reduced the hypoxia-induced increase in IL-6 and TIMP-1 as well as the chemoattractants, CXCL2, CXCL3, CXCL5 and CXCL10. Spironolactone and FAD286 reduced the levels of CXCL2 and CXCL10, respectively. In conclusion, our findings that both Ang II and aldosterone influence the activation of retinal microglia implicates the renin-angiotensin aldosterone system in the pathogenesis of ischemic retinopathies.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Aldosterone; Angiotensin II; Chemokines; Microglia; NADPH oxidase; Reactive oxygen species

Mesh:

Substances:

Year:  2019        PMID: 31884019     DOI: 10.1016/j.exer.2019.107902

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  4 in total

1.  Ablation of lysozyme M-positive cells prevents aircraft noise-induced vascular damage without improving cerebral side effects.

Authors:  Thomas Münzel; Sebastian Steven; Katie Frenis; Johanna Helmstädter; Yue Ruan; Eva Schramm; Sanela Kalinovic; Swenja Kröller-Schön; Maria Teresa Bayo Jimenez; Omar Hahad; Matthias Oelze; Subao Jiang; Philip Wenzel; Clemens J Sommer; Katrin B M Frauenknecht; Ari Waisman; Adrian Gericke; Andreas Daiber
Journal:  Basic Res Cardiol       Date:  2021-04-30       Impact factor: 17.165

Review 2.  The role of inflammation and neurodegeneration in diabetic macular edema.

Authors:  Vincenzo Starace; Marco Battista; Maria Brambati; Michele Cavalleri; Federico Bertuzzi; Alessia Amato; Rosangela Lattanzio; Francesco Bandello; Maria Vittoria Cicinelli
Journal:  Ther Adv Ophthalmol       Date:  2021-12-05

3.  Angiotensin II related glial cell activation and necroptosis of retinal ganglion cells after systemic hypotension in glaucoma.

Authors:  Soo Ji Jeon; Jungbin Huh; Eojin Jeong; Chan Kee Park; Hae Young Lopilly Park
Journal:  Cell Death Dis       Date:  2022-04-09       Impact factor: 8.469

Review 4.  NOX2 Activation in COVID-19: Possible Implications for Neurodegenerative Diseases.

Authors:  Cinzia Sindona; Giovanni Schepici; Valentina Contestabile; Placido Bramanti; Emanuela Mazzon
Journal:  Medicina (Kaunas)       Date:  2021-06-11       Impact factor: 2.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.